+ Most Popular
Cunninghamia lanceolata plantations in China
Mammalian lairs in paleo ecological studies and palynology
Studies on technological possibilities in utilization of anhydrous milk fat for production of recombined butter-like products
Should right-sided fibroelastomas be operated upon?
Large esophageal lipoma
Apoptosis in the mammalian thymus during normal histogenesis and under various in vitro and in vivo experimental conditions
Poissons characoides nouveaux ou non signales de l'Ilha do Bananal, Bresil
Desensitizing efficacy of Colgate Sensitive Maximum Strength and Fresh Mint Sensodyne dentifrices
Administration of fluid by subcutaneous infusion: revival of a forgotten method
Tundra mosquito control - an impossible dream?
Schizophrenia for primary care providers: how to contribute to the care of a vulnerable patient population
Geochemical pattern analysis; method of describing the Southeastern limestone regional aquifer system
Incidence of low birth weights in a hospital of Mexico City
Graded management intensity of grassland systems for enhancing floristic diversity
Microbiology and biochemistry of cheese and fermented milk
The ember tetra: a new pygmy characid tetra from the Rio das Mortes, Brazil, Hyphessobrycon amandae sp. n. (Pisces, Characoidei)
Risk factors of contrast-induced nephropathy in patients after coronary artery intervention
Renovation of onsite domestic wastewater in a poorly drained soil
Observations of the propagation velocity and formation mechanism of burst fractures caused by gunshot
Systolic blood pressure in a population of infants in the first year of life: the Brompton study
Haematological studies in rats fed with metanil yellow
Studies on pasteurellosis. I. A new species of Pasteurella encountered in chronic fowl cholera
Dormancy breaking and germination of Acacia salicina Lindl. seeds
therapy of lupus nephritis. a two-year prospective study

Use of phentermine-topiramate extended release in combination with sleeve gastrectomy in patients with BMI 50 kg/m 2 or more

Use of phentermine-topiramate extended release in combination with sleeve gastrectomy in patients with BMI 50 kg/m 2 or more

Surgery for Obesity and Related Diseases: Official Journal of the American Society for Bariatric Surgery 15(7): 1039-1043

ISSN/ISBN: 1550-7289

PMID: 31147285

DOI: 10.1016/j.soard.2019.04.017

Super obesity (body mass index [BMI] ≥50 kg/m2) treatment can be complicated and high risk. We studied whether the pre and postoperative use of phentermine and topiramate (phen/top) combined with laparoscopic sleeve gastrectomy (LSG) in super obesity increases the odds of achieving a BMI <40 at 2 years postoperatively. Academic medical center in Winston Salem, North Carolina. We recruited patients between 2014 and 2016 who had a BMI ≥50 and planned to undergo LSG (n = 25) to participate in an open-label trial. Participants took phen/top (7.5/46-15/92 mg/d) for at least 3 months preoperatively and 2 years postoperatively. We compared weight loss, BMI changes, and odds for achieving BMI <40 for phen/top + LSG to historical controls. Controls had an initial BMI ≥50 and underwent LSG, without phen/top, at our center during the same timeframe (n = 40). Of the 25 participants recruited, 13 completed LSG. Phen/top participants had a baseline BMI of 61.2 ± 7.1 kg/m2 compared with 57.0 ± 5.6 kg/m2 for control participants. Percent initial weight loss was -39.3% (phen/top + LSG) versus -31.4% (control) at 12 months, P = .018; by 24 months, phen/top + LSG had an 11.2% greater initial weight loss, P = .007. At 24 months, the mean BMI was 33.8 kg/m2 for phen/top versus 42 kg/m2 for controls. The odds ratio for achieving a BMI <40 at 2 years with phen/top + LSG versus LSG alone was 4.1 (95% confidence interval, 0.8-21). Compared with LSG alone, phen/top combined with LSG may help patients with a BMI >50 achieve greater weight loss and reach a BMI <40. Long-term, controlled trials are needed to follow up these results.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 072845485

Download citation: RISBibTeXText

Related references

Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release. Expert Opinion on Drug Safety 16(1): 27-39, 2017

Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity 21(11): 2163-2171, 2013

Combination phentermine and topiramate extended release in the management of obesity. Expert Opinion on PharmacoTherapy 16(8): 1263-1274, 2015

A Review of the Combination of Phentermine and Topiramate Extended-Release for Weight Loss. Combination Products in Therapy 2(1), 2012

Successful Treatment of Binge Eating Disorder With Combination Phentermine/Topiramate Extended Release. Primary Care Companion for Cns Disorders 17(2), 2015

Combination Phentermine-Topiramate Extended Release for the Treatment of Binge Eating Disorder: An Open-Label, Prospective Study. Innovations in Clinical Neuroscience 15(5-6): 17-21, 2018

Phentermine/Topiramate Extended Release. Hospital Pharmacy 47(12): 950-958, 2012

Second prospective, Pharmacoepidemiologic database analysis of Phentermine and Topiramate extended-release usage from a representative us sample of Older Patients. Value in Health 18(3): A293-A294, 2015

Budget impact of phentermine and topiramate extended-release (PHEN/TPM ER) in overweight and obese patients with comorbid prediabetes or type 2 diabetes mellitus (T2DM). Value in Health 17(3): A242-A243, 2014

Phentermine and topiramate extended release (Qsymia™): first global approval. Drugs 72(15): 2033-2042, 2012

Phentermine and topiramate extended-release for the obesity: new kids on the block. Recent Patents on Cardiovascular Drug Discovery 8(1): 35-41, 2013

Phentermine/Topiramate extended-release capsules (qsymia) for weight loss. P and T: a Peer-Reviewed Journal for Formulary Management 38(8): 446-452, 2013

Management of obesity and cardiometabolic risk - role of phentermine/extended release topiramate. Diabetes Metabolic Syndrome and Obesity: Targets and Therapy 7: 35-44, 2014

Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care 37(12): 3309-3316, 2014

Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2). American Journal of Cardiology 111(8): 1131-1138, 2013